Baird Financial Group Inc. Reduces Stock Position in Insulet Corporation $PODD

Key Points

• Baird Financial Group Inc. has reduced its stake in Insulet Corporation by 14.2%, selling 41,715 shares in the first quarter, bringing its total ownership to 252,900 shares valued at approximately $66.4 million.
• Insulet reported earnings of $1.17 per share for the last quarter, surpassing analysts' expectations of $0.92, with revenue increasing by 32.9% year-over-year.
• Analysts maintain a positive outlook on Insulet, with a consensus rating of "Moderate Buy" and a target price of $332.71, indicating strong investor confidence in the company's performance.

Baird Financial Group Inc. decreased its position in Insulet Corporation (NASDAQ:PODD - Free Report) by 14.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 252,900 shares of the medical instruments supplier's stock after selling 41,715 shares during the period. Baird Financial Group Inc. owned approximately 0.36% of Insulet worth $66,414,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Larson Financial Group LLC increased its holdings in shares of Insulet by 426.3% during the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock valued at $26,000 after acquiring an additional 81 shares in the last quarter. Zions Bancorporation National Association UT purchased a new stake in Insulet in the 1st quarter valued at about $26,000. SouthState Corp raised its stake in shares of Insulet by 253.3% during the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock worth $28,000 after purchasing an additional 76 shares during the period. Itau Unibanco Holding S.A. purchased a new position in Insulet in the fourth quarter valued at approximately $42,000. Finally, Ramirez Asset Management Inc. purchased a new position in shares of Insulet in the first quarter worth about $53,000.

Insulet Trading Up 0.9%

Insulet stock traded up $2.94 during mid-day trading on Thursday, hitting $346.47. The company's stock had a trading volume of 276,668 shares, compared to its average volume of 753,727. The business has a 50 day moving average price of $306.11 and a 200-day moving average price of $288.90. Insulet Corporation has a 12 month low of $211.27 and a 12 month high of $350.00. The stock has a market cap of $24.39 billion, a price-to-earnings ratio of 105.31, a price-to-earnings-growth ratio of 2.85 and a beta of 1.36. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD - Get Free Report) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating analysts' consensus estimates of $0.92 by $0.25. The company had revenue of $649.10 million during the quarter, compared to analyst estimates of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.Insulet's revenue for the quarter was up 32.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, analysts forecast that Insulet Corporation will post 3.92 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on PODD shares. The Goldman Sachs Group started coverage on Insulet in a research report on Friday, May 30th. They issued a "buy" rating and a $380.00 price target for the company. Jefferies Financial Group reiterated a "buy" rating on shares of Insulet in a research report on Thursday, August 7th. Truist Financial initiated coverage on shares of Insulet in a report on Monday, June 16th. They issued a "buy" rating and a $365.00 price target on the stock. Sanford C. Bernstein reaffirmed an "outperform" rating on shares of Insulet in a research note on Friday, May 16th. Finally, Oppenheimer increased their target price on shares of Insulet from $312.00 to $324.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. Sixteen analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $332.71.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.